Share this video  

ASCO 2021 | OlympiA: adjuvant olaparib following chemo significantly improves IDFS

Evandro de Azambuja, MD, PhD, L’Universite Libre de Bruxelles, Brussels, Belgium, talks on the results of the OlympiA trial (NCT02032823), a randomized Phase III study enrolling patients with germline BRCA mutant and HER2 negative high-risk early breast cancer after primary local treatment and adjuvant or neoadjuvant chemotherapy. In this patient population, adjuvant olaparib following adjuvant or neoadjuvant chemotherapy significantly improved invasive disease-free survival and distant disease-free survival with acceptable toxicity in patients with germline BRCA mutant and high-risk HER2-negative early breast cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.


Evandro de Azambuja, MD, PhD, has received honoraria and advisory board roles from Roche/GNE, Novartis, Seattle Genetics, Zodiacs, Lilly, Libbs and Pierre Fabre; travel grants from Roche/GNE and GSK/Novartis; research grants for his institute (IJB) from Roche/GNE, Astra-Zeneca, Novartis, and Servier.